Mindset Pharma Selects Treatment-Resistant Depression and End of Life Cancer Angst as Indications for MSP-1014, its NoveHow Will The Data Protection Ruling On Ketamine Impact Psychedelic Novel Drug Development Moving Forward?Mindset Pharma Announces its Next Generation Novel 5-MeO-DMT Psychedelic AnalogsSilo Pharma Advances Psychedelic Patent PortfolioTryp Therapeutics Completes Psychotherapy Training for Phase 2a Study at the University of FloridaMajor Psychedelic Clinical Trial Data Is Right Around The CornerPsychedelic Drug Development Companies Are Leveraging Bolt On MedTech Acquisitions To Create A More Robust Patient Care 7 Psychedelic Clinical Trials Underway That Investors Should Keep On Their RadarNuminus Wellness Closes Q3 2021 With $63.2 Million Cash Position, Lab and Trial Advances, and Strategic Expansion into PSilo Pharma Awarded Notice of Allowance from United States Patent and Trademark Office for Homing Peptide PatentTryp Therapeutics Announces Q3 2021 Financial ResultsKetamine One’s IRP Clinic Using Innovative NeuroCatch Platform to Measure Brain Function in Injured VeteransWake Network, Inc. and the Lieber Institute for Brain Development Announce Research CollaborationTryp Therapeutics Announces Plans for Phase 2a Clinical Trial for Fibromyalgia with the University of MichiganNuminus Wellness Reaches Major Milestone With MAPS Sponsored MDMA StudyNuminus Announces Health Canada Approval of MAPS-Sponsored Open Label Study for MDMA-Assisted Therapy for PTSDPsyence Group and UK Psychedelic CRO Partners to Conduct UK Palliative Care Clinical TrialTryp Therapeutics Partners with the University of Michigan to Evaluate Proprietary FormulationsPsyched Wellness Commences Next Pre-Clinical Study on AME-1Atai Life Sciences Is Setting The Standard For Psychedelic Drug Development

Technical420 Site Search

Returned 150 result(s).

Numinus Wellness Is One Of The Shining Stars Of The Psychedelic Sector

So far this year, Numinus Wellness Inc. (TSXV: NUMI) (OTC: LKYSF) has been one of the most active psychedelic companies. The mental health care company is working to bring innovative and evidence-based psychedelic-assisted therapies to market and we are closely following the business.  Numinus is comprised of several divisions and…

Psychedelic Stocks Are Starting To Get Some Serious Traction In The Mainstream Media

2021 has been a banner year for the psychedelic therapy market and we believe the industry is in the early innings of a major growth cycle.  With interest growing for data from biotech and non-profit research firms that are conducting Food and Drug Administration (FDA) clinical trials on psychedelic therapies.…

MAPS Canada Is Leading The Way For Psychedelic Use Cases In Modern Medicine

After the Multidisciplinary Association for Psychedelic Studies (MAPS) published promising results from a clinical trial using MDMA to treat post-traumatic stress disorder (PTSD), the psychedelic therapy sector has received extra attention.  According to The New York Times, MAPS could receive FDA approval by 2023 and we are favorable on the…

Tryp Therapeutics Partners with Clinlogix for Clinical Trial Support

 Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) (FSE: 8FW) ("Tryp"), a pharmaceutical company focused on developing clinical-stage compounds for diseases with unmet medical needs, announced today a master service agreement with Clinlogix, a Contract Research Organization (CRO), to support Tryp's clinical development of its Psilocybin-for-Neuropsychiatric Disorders (PFNTM) program. Clinlogix has global experience with providing…

Tryp Therapeutics Announces Q2 2021 Financial Results

Tryp Therapeutics Inc. (CSE: TRYP), today announced its interim financial results for the three and six month periods ended February 28, 2021. Complete financial statements along with related management discussion and analysis can be found in the System for Electronic Document Analysis and Retrieval, the electronic filing system for the…

Pure Extracts Dual Vertical Approach Incorporating Cannabis and Psychedelic Compounds Is Starting To Pay Off

During the last month, Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) has reported several significant developments and is an opportunity that we are closely following. From forming strategic partnerships to purchasing cannabis biomass to launch a line of cannabis 2.0 products, Pure Extracts has been executing on…

Cybin Announces Senior Management Changes to Lead Buildout of Development and Clinical Capabilities in the United States and Europe

-Cybin Inc. (NEO:CYBN) (OTCQB:CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, today announced key senior management changes to lead the buildout of its development and clinical operations in the United States and Europe. Effective immediately, Alexander Belser, PhD, will serve as Chief Clinical Officer, and Aaron Bartlone will serve as…

MushroomStocks.com Deep Dive: Tryp Therapeutics (CSE:TRYP)

Over the past year there has been a significant increase in interest in companies that are focused on the psychedelic therapy market--a trend that we are following closely. Interest in these companies has been steadily rising in 2021, and we are focused on identifying businesses that have staying power. Tryp…

Field Trip Has A Warchest Of Cash To Propel R&D and M&A Moving Forward

If you have not been following Field Trip Health Ltd. (CSE: FTRP) (OTCQX: FTRPF), you may want to put the company on your radar after it closed a massive private placement. Last week, Field Trip reported to have closed a previously announced $95 million bought deal short form prospectus offering.…

Rritual Announces Successful Completion of Second Full Scale Manufacturing Run and Commencement of Third Full Scale Manufacturing Run in Early April

Rritual Superfoods Inc. (CSE: RSF) (CSE: RSF.WT) is pleased to provide an update on its upcoming US retail launch of its plant-based superfood elixirs. Rritual has successfully completed a second commercial scale manufacturing run which is approximately  50% larger than its initial production run.  Production for early April is scheduled and…

Older Posts »

Search Again

The psychedelics sector is starting to take off as smart money begins to position itself across the industry.

Stay updated with all latest updates,upcoming events & much more.
Subscribe
SUBSCRIBE NOW
close-link